Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naomi L Kruhlak

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
Toxicology|April 12, 2014
Construction and analysis of a human hepatotoxicity database suitable for QSAR modeling using post-market safety dataXiao Zhu, Naomi L Kruhlak
Regulatory Toxicology and Pharmacology : RTP|October 3, 2018
Construction and application of (Q)SAR models to predict chemical-induced in vitro chromosome aberrationsChia-Wen Hsu, Kurt P Hewes, Lidiya Stavitskaya, et al.
Expert Opinion on Drug Metabolism & Toxicology|January 16, 2010
A structural feature-based computational approach for toxicology predictionsLuis G Valerio, Chihae Yang, Kirk B Arvidson, et al.
Regulatory Toxicology and Pharmacology : RTP|January 9, 2007
A comprehensive model for reproductive and developmental toxicity hazard identification: I. Development of a weight of evidence QSAR databaseEdwin J Matthews, Naomi L Kruhlak, R Daniel Benz, et al.
Regulatory Toxicology and Pharmacology : RTP|November 18, 2004
Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily doseJoseph F Contrera, Edwin J Matthews, Naomi L Kruhlak, et al.
Current Drug Discovery Technologies|February 14, 2006
Assessment of the health effects of chemicals in humans: I. QSAR estimation of the maximum recommended therapeutic dose (MRTD) and no effect level (NOEL) of organic chemicals based on clinical trial dataEdwin J Matthews, Naomi L Kruhlak, R Daniel Benz, et al.
Advanced Drug Delivery Reviews|January 19, 2007
Progress in QSAR toxicity screening of pharmaceutical impurities and other FDA regulated productsNaomi L Kruhlak, Joseph F Contrera, R Daniel Benz, et al.
Regulatory Toxicology and Pharmacology : RTP|August 21, 2007
Comparison of MC4PC and MDL-QSAR rodent carcinogenicity predictions and the enhancement of predictive performance by combining QSAR modelsJoseph F Contrera, Naomi L Kruhlak, Edwin J Matthews, et al.
Molecular Informatics|August 2, 2016
Construction and Consensus Performance of (Q)SAR Models for Predicting Phospholipidosis Using a Dataset of 743 CompoundsAmabel M Orogo, Sydney S Choi, Barbara L Minnier, et al.
Regulatory Toxicology and Pharmacology : RTP|October 26, 2005
In silico screening of chemicals for bacterial mutagenicity using electrotopological E-state indices and MDL QSAR softwareJoseph F Contrera, Edwin J Matthews, Naomi L Kruhlak, et al.
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
Toxicology|April 12, 2014
Construction and analysis of a human hepatotoxicity database suitable for QSAR modeling using post-market safety dataXiao Zhu, Naomi L Kruhlak
Regulatory Toxicology and Pharmacology : RTP|October 3, 2018
Construction and application of (Q)SAR models to predict chemical-induced in vitro chromosome aberrationsChia-Wen Hsu, Kurt P Hewes, Lidiya Stavitskaya, et al.
Expert Opinion on Drug Metabolism & Toxicology|January 16, 2010
A structural feature-based computational approach for toxicology predictionsLuis G Valerio, Chihae Yang, Kirk B Arvidson, et al.
Regulatory Toxicology and Pharmacology : RTP|January 9, 2007
A comprehensive model for reproductive and developmental toxicity hazard identification: I. Development of a weight of evidence QSAR databaseEdwin J Matthews, Naomi L Kruhlak, R Daniel Benz, et al.
Regulatory Toxicology and Pharmacology : RTP|November 18, 2004
Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily doseJoseph F Contrera, Edwin J Matthews, Naomi L Kruhlak, et al.
Current Drug Discovery Technologies|February 14, 2006
Assessment of the health effects of chemicals in humans: I. QSAR estimation of the maximum recommended therapeutic dose (MRTD) and no effect level (NOEL) of organic chemicals based on clinical trial dataEdwin J Matthews, Naomi L Kruhlak, R Daniel Benz, et al.
Advanced Drug Delivery Reviews|January 19, 2007
Progress in QSAR toxicity screening of pharmaceutical impurities and other FDA regulated productsNaomi L Kruhlak, Joseph F Contrera, R Daniel Benz, et al.
Regulatory Toxicology and Pharmacology : RTP|August 21, 2007
Comparison of MC4PC and MDL-QSAR rodent carcinogenicity predictions and the enhancement of predictive performance by combining QSAR modelsJoseph F Contrera, Naomi L Kruhlak, Edwin J Matthews, et al.
Molecular Informatics|August 2, 2016
Construction and Consensus Performance of (Q)SAR Models for Predicting Phospholipidosis Using a Dataset of 743 CompoundsAmabel M Orogo, Sydney S Choi, Barbara L Minnier, et al.
Regulatory Toxicology and Pharmacology : RTP|October 26, 2005
In silico screening of chemicals for bacterial mutagenicity using electrotopological E-state indices and MDL QSAR softwareJoseph F Contrera, Edwin J Matthews, Naomi L Kruhlak, et al.
Pageof 4